NCT04990024Completed
The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
The Effect of Mediterranean or High Protein/Low Carbohydrate Diet on Arterial Stiffness in Non-diabetic, Obese Patients on Semaglutide: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
In patients initiating Semaglutide for weight management, the objective is to compare the effect of the Mediterranean diet and the high protein/low carbohydrate (HP/LC) diet CV parameters, namely arterial stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), and visceral adipose tissue, in addition to other metabolic indicators.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 31 (actual)
- First submitted
- 2 Jul 2021
- Start date
- 1 Jul 2021
- Primary completion date
- 15 Dec 2025
- Lead sponsor
- American University of Beirut Medical Center
- Diseases
- Obesity
- NCT number
- NCT04990024
What you commit to
- Study type: Interventional
- Participants enrolled: 31
- From 1 Jul 2021 to the primary completion date, 15 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are taking or have taken other weight reducing drug therapies in the previous 6 months
- Patients who have undergone metabolic weight loss surgery
- Patients who have undergone bariatric surgery
Other illness
- Patients with uncontrolled hypertension
- Patients with uncontrolled cardiac disease, pulmonary, renal or liver diseases, active cancer or psychiatric diseases
- Patients known to have uncontrolled/ untreated thyroid disorders.
- Patients with cushing disease or polycystic ovaries, and those with neuro-endocrine or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy): Such patients are resistant to weight loss, and they need treatment of their primary disease and/or cessation of the culprit medication to lose weight
Lab values
- Patients known to have diabetes (HbA1c ≥6.5% at screening)
Other
- Pregnant women
- Patients with excessive alcohol intake, defined as ≥ 2 glasses per day
- Patients with untreated gout
Who the study is looking for
- Men and premenopausal women, 18-49 years, with obesity defined as BMI ≥ 30 kg/m2
- Upon the initiation of Semaglutide (within the first 1-4 weeks) for medical weight management, for clinical purposes, as advised by the primary physician
- Able to commit for a 6-month trial visits
Age in the registry: 18 years to 49 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| American University of Beirut Medical Center Coordinator of this site? Confirm its status | Beirut | Lebanon | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.